



PQA: Quality Measure Expert Panel

(QMEP)



Discussion of Process and Recommendations November 10, 2009





Why was QMEP created?



- Measure development is resource intensive and resource dependent.
- QMEP was created to review measure concepts and determine which are ready to proceed to the next phase of development and testing.
- This additional step, using PQA's member expertise, prior to partnering with an Measure Development Organization, should be more efficient/economical.



Members of the QMEP:



Co-chairs of the QMEP are:

Julie Kuhle, Iowa Foundation for Medical Care

Kent Summers, Endo Pharmaceuticals

PQA members serving on this Committee are:

Lawrence Brown, University of Tennessee, College of Pharmacy

Carey Cotterell, Kaiser Permanente

Eric Culley, Highmark

Patrick Gleason, Prime Therapeutics

Mary Ann Kliethermes, Midwestern University

Lynn Martin, URAC

David Nau, Humana

Bimal Patel, MedImpact

Lynn Pezzulo, Quality Partners

Marissa Schlaifer, AMCP

Brad Tice, PharmMD


Kristina Yu-Isenberg, Novartis



Process



PQA-approved Measure Concepts





Evaluation Criteria



- 1. Specify outcome measured (e.g. clinical outcome, process, structure, access)**
- 2. Specify care setting measured (e.g. Prescription Drug Plan, Pharmacy, MTM provider)**
- 3. Determine if a pharmacist can impact the measure alone or if the prescriber's approval is needed to impact the measure**
- 4. Determine what data is needed for the measure and the source and quality of the data available**
- 5. Measure rating (scale of 1-5):**
 - A. Importance**
 - B. Scientific acceptability**
 - C. Usability**
 - D. Feasibility**



Determination of Readiness

partially depends on availability of data sources



- Measure development is possible when existing databases contain sufficient data to calculate a measure (and when that data is “aggregate-able”)
- When commonly available data sources do not contain sufficient data or collection of primary data is required, then measure development becomes very difficult, expensive



Measure Concepts Reviewed & Evaluated



In November 2008, the PQA membership approved a total of 31 new measure concepts.

The QMEP held six conference calls from May-July 2009 to review the following:

<i>FOCUS AREA</i>	<i># of Measures</i>
<i>Cardiovascular:</i>	3
<i>Diabetes:</i>	3
<i>Medication Therapy Management:</i>	4
<i>Medication Adherence:</i>	2
<i>Mental Health:</i>	3
<i>Patient Safety:</i>	2
<i>Medication Reconciliation:</i>	5
<i>Prevention and Wellness:</i>	2



Results: Measure Concepts Recommended

For Immediate Development



Cardiovascular:

Rate of use of drugs for dyslipidemia in CAD

MTM:

Comprehensive Medication Review (CMR)

Medication Adherence:

Proportion of Days Covered: HIV/AIDS Medications

Proportion of Days Covered: Anticonvulsant Medications

Patient Safety:

High Alert Drug Review, Indicator 1 and Indicator 2

Respiratory Disorders:

Asthma therapy with LABAs



Results: Measure Concepts Recommended

For Future Development



Cardiovascular:

INR monitoring at least monthly

Avoidance of chronic NSAID use in heart failure

Diabetes:

Percent of patients receiving at least 2 HbA1c/year

Percent of patients receiving at least one micro-albumin urine screen/year

Percent of patients receiving at least one LDL-C screening/year

MTM:

Patients receiving service

Declined to enroll

Personal Medication List

Medication Adherence:

Antidepressant – Gap in Therapy

Proportion of Days Covered: Antidepressants –Continuation Phase

Proportion of Days Covered: Antidepressants – Acute Phase



Results: Measure Concepts Recommended

For Future Development



Medication Reconciliation:

Patient Personal Medication List Portability

Evidence of a Patient's Personal Medication List

Patient's Personal Medication List Discrepancies Resolved

Personal Medication List Creation

Patient's Personal Medication List, Comprehensive Review and Reconciliation

Respiratory Disorders:

Appropriateness of COPD therapy with LABA

Suboptimal asthma control

Wellness and Prevention:

Tobacco Cessation Interventions – four sub-measure concepts

Influenza vaccination – screening

Influenza vaccination – received vaccine from pharmacist

Influenza vaccination – received vaccine as a result of pharmacist facilitation



Next Steps:



PQA's Board considers approval of moving 7 measure concepts to testing stage with an MDO.

QMEP reviews all PQA-endorsed measure concepts from this meeting and makes recommendations by 1/31/10.

Then, PQA can send the 2008/2009 measure concept "set" together to an MDO in early February 2010.



Coming Soon:

PQA Libraries of Measures and Measure Concepts

See PQA Website (January 2010)



PQA to Create Four Libraries of Measures:

- PQA/NCQA measures that *have* received NQF endorsement
- PQA/NCQA measures that are *not* NQF-endorsed
- PQA-approved measure concepts (*have not* undergone testing and development)
- PQA-approved measure concepts (that are *undergoing* testing and development)